Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Eprenetapopt - Aprea

Next Previous
X
Search
Drug Profile

Eprenetapopt - Aprea

Alternative Names: APR-246; PRIMA-1-MET

Latest Information Update: 28 May 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Aprea
  • Developer Aprea Therapeutics; H. Lee Moffitt Cancer Center and Research Institute; Jules Bordet Institute; Peter MacCallum Cancer Centre; University of Missouri-Columbia; Victorian Cancer Agency
  • Class Antineoplastics; Aza compounds; Ketones; Quinuclidines; Small molecules
  • Mechanism of Action Apoptosis stimulants; Thioredoxin reductase inhibitors; Tumour suppressor protein p53 stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Myelodysplastic syndromes; Acute myeloid leukaemia; Ovarian cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Acute myeloid leukaemia; Breast cancer; Chronic lymphocytic leukaemia; Chronic myelomonocytic leukaemia; CNS cancer; Endometrial cancer; Gastric cancer; Haematological malignancies; Lung cancer; Malignant melanoma; Mantle-cell lymphoma; Myelodysplastic syndromes; Non-small cell lung cancer; Oesophageal cancer; Ovarian cancer; Prostate cancer; Urogenital cancer

Most Recent Events

  • 26 Mar 2024 Discontinued - Phase-I/II for Acute myeloid leukaemia (Combination therapy) in USA (IV)
  • 26 Mar 2024 Discontinued - Phase-I/II for Chronic lymphocytic leukaemia (Combination therapy, Second-line therapy or greater) in USA (IV)
  • 26 Mar 2024 Discontinued - Phase-I/II for Chronic myelomonocytic leukaemia (Combination therapy) in USA (IV)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top